Libenzapril (Abutapril; CGS-16617) is an orally active, potent direct-acting angiotensin-converting-enzyme (ACE) inhibitor. Libenzapril has the potential for ischemia-induced heart failure research.
Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Endocrinology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Angiotensin-converting Enzyme (ACE)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.